Status:
COMPLETED
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
Lead Sponsor:
Mayo Clinic
Conditions:
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Eligibility:
All Genders
Phase:
EARLY_PHASE1
Brief Summary
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomic...
Detailed Description
PRIMARY OBJECTIVES: I. Evaluate patient perceptions surrounding their quality of life (QOL) prior to pharmacogenomics (PGx) testing and 3 months post PGx testing. II. Understand the clinical utility...
Eligibility Criteria
Inclusion
- Patient enrolled to Mayo Clinic IRB: 18-000326
- Patients with stage 3 or 4 breast, colorectal, prostate/genitourinary (GU), pancreato-biliary, brain, melanoma, and ovarian cancer
- Individuals have agreed to participate and signed the study informed consent form
Exclusion
- Patients with cancer types other than the ones mentioned above
- Patient with psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
- Previous PGx testing with results available within Mayo Clinic electronic medical record (EMR)
Key Trial Info
Start Date :
June 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 6 2022
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT04067960
Start Date
June 6 2019
End Date
October 6 2022
Last Update
August 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259